Progenics planning follow-on

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) proposed late Wednesday a follow-on underwritten by Jefferies. Earlier this month, partner Salix Pharmaceuticals Inc. (NASDAQ:SLXP) said FDA will convene an advisory committee meeting to discuss Salix's appeal of a complete response letter for subcutaneous Relistor methylnaltrexone to treat opioid-induced constipation (OIC) in patients with chronic pain. Relistor is already approved in more than 55 countries, including the U.S., to treat OIC in patients receiving palliative care when response to laxative therapy has not been sufficient. Salix has worldwide rights to the peripheral mu opioid receptor ( OPRM1; MOR) antagonist from Progenics (see BioCentury Extra, June 11). ...